Fidelity Freedom 2030 Fund Q4 2024 Review
Source: SeekingAlpha
2025-03-17 20:49:00 ET
Summary
- The fourth quarter of 2024 was volatile for most asset classes against a backdrop of the U.S. election, surging dollar strength, sticky inflation and rising interest rates in some markets.
- Active asset allocation decisions detracted from the Fund's performance versus the Fidelity Freedom® 2030 Composite Index in Q4, whereas the investment performance of the underlying portfolios contributed.
- The Fund's glide path and strategic asset allocation reflect our long-term views and insights on participant needs, diversification and capital markets.
Performance Summary
| Cumulative | Annualized | |||||
| 3 | 1 | 3 | 5 | 10 Year/ LOF1 | ||
| Month | YTD | Year | Year | Year | ||
| Fidelity Freedom 2030 Fund Gross Expense Ratio: 0.65%2 | -2.93% | 9.23% | 9.23% | 1.53% | 6.16% | 7.04% |
| S&P 500 Index | 2.41% | 25.02% | 25.02% | 8.94% | 14.53% | 13.10% |
| Fidelity Freedom 2030 Composite Index | -2.34% | 9.69% | 9.69% | 1.71% | 6.00% | 7.07% |
| Morningstar Fund Target-Date 2030 | -2.09% | 9.46% | 9.46% | 1.67% | 5.93% | 6.43% |
| % Rank in Morningstar Category (1% = Best) | -- | -- | 66% | 63% | 43% | 14% |
| # of Funds in Morningstar Category | -- | -- | 209 | 197 | 171 | 112 |
Read the full article on Seeking Alpha
For further details see:
Fidelity Freedom 2030 Fund Q4 2024 Review
AstraZeneca PLC
NASDAQ: AZN
AZN Trading
9.5% G/L:
$93.12 Last:
2,417,086 Volume:
$93.03 Open:
AZN Latest News
March 10, 2026 08:30:00 am
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
March 09, 2026 08:05:00 am
Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
AZN Stock Data
$606,922,468,616
3,070,437,221
0.1%
781
N/A
Pharmaceuticals
Healthcare
GB
Cambridge
